The advent of genome editing has transformed the therapeutic landscape for several
debilitating diseases, and the clinical outlook for gene therapeutics has never been more …

Five small interfering RNA (siRNA)-based therapeutics have been approved by the Food
and Drug Administration (FDA), namely patisiran, givosiran, lumasiran, inclisiran, and …

Simple Summary Cancer is one of the leading causes of death globally. Several studies,
efforts and treatment strategies have been put forth for the treatment of different types of …

Most therapeutic agents suffer from poor solubility, rapid clearance from the blood stream, a
lack of targeting, and often poor translocation ability across cell membranes. Drug/gene …

Abstract Inherited Retinal Diseases (IRDs) are considered one of the leading causes of
blindness worldwide. However, the majority of them still lack a safe and effective treatment …

It is a great challenge for nanomedicine to develop novel dendrimers with maximum
therapeutic potential and minimum side-effects for drug and gene delivery. As delivery …

Tools for editing the genome and epigenome have revolutionised the field of molecular
biology and represent a new frontier in targeted therapeutic intervention. Although …

The discovery of RNA interference (RNAi) has excited the scientific field due to its potential
for wide range of therapeutic applications. The pharmacological mediator of RNAi, short …

RNA interference (RNAi) was first literaturally reported in 1998 and has become rapidly a
promising tool for therapeutic applications in gene therapy. In a typical RNAi process, small …

Dendrimers comprise a specific group of macromolecules, which combine structural
properties of both single molecules and long expanded polymers. The three-dimensional …